Science Outreach

Advancing animal-free science in Australia

AFSA is driving the transition towards a future where Australian science is powered by innovation, human relevance and cutting-edge approaches that move beyond animal-based research.

Through scientific leadership, advocacy, sector engagement and strategic collaboration, AFSA is shaping the direction of animal-free science in Australia — bringing together researchers, educators, industry leaders, regulators and decision-makers to accelerate the development and adoption of Non-Animal Methodologies (NAMs).

From conference presentations and scientific publications to policy development, university engagement, industry partnerships and more, AFSA is building the knowledge, connections and momentum needed to transform Australian science. As a trusted leader in this emerging field, AFSA provides expertise, evidence-based resources and strategic guidance to drive the shift towards more predictive, efficient and human-relevant research models — positioning Australia at the forefront of the global transition to animal-free science.

AFSA's Satellite Event at AusBioTech 2026

AFSA is proud to host a dedicated satellite event as part of the 2026 AusBioTech Conference — Australia’s largest life sciences gathering.

This landmark session brings together leading voices from across research, biotechnology, regulation, education, investment and policy for a rare opportunity to collaborate on the future of non-animal science in Australia.

For the first time, key stakeholders from across the Australian science ecosystem will come together with a shared focus: advancing a National Collaborative Platform for Non-animal Technologies.

Supported by Voiceless, this event builds on the momentum generated by CSIRO’s landmark 2023 Non-Animal Models Strategy for Australia and the Non-animal technologies network (NAT-Net) establishment in 2024. The session will explore how Australia can move from recommendations to implementation – supporting capability building, collaboration, translation and adoption.

The event will showcase Australian innovation, highlight existing leadership in the field and create connections between the people and organisations who can drive this transformation forward.

📅 Monday October 19th, 2026 · 13:00 – 18:00     📍Gold Coast Convention and Exhibition CentreBroadbeach, QLD

Program Agenda

13:00 – Welcome and introductions to key speakers
             Dr Natalie Anderson, Erica Bremner Kneipp, Dr Kathrin Herrmann

13:40 – Panel 1: Building Confidence and Capability in NAMs
            Chaired by Dr Michelle Lam

14:20 – Panel 2: Data sharing, services, resources and national infrastructure
            Chaired by Prof Michael Dobbie

15:00 – Break

15:10 – Global Education Hub for animal-free innovation
            Professor Wojciech Chrzanowski

15:20 – Workshops (20min per table):

             Table 1 – Regulatory pathways and commercialisation
             Table 2 – Infrastructure, data sharing and access
             Table 3 – Education and workforce development
             Table 4 – The National Collaborative Platform for Non-animal Technologies, national policies, statistics and public communication

16:45 – Presentations of workshop outcomes (5min per table)

17:05 – Steering committee and NAMs statement sign-up

17:10 – Networking and refreshments

17:40 – Draft workshop report

17:55 – Close

Key Speakers

Dr Natalie Anderson

Animal-Free Science Advocacy


Natalie holds a PhD in Public Health, a Master’s in Child Health Research and a Bachelor of Science in Human Biology. An experienced medical researcher, she has presented on animal-free science at leading scientific forums and serves on the editorial board of the Alternatives to Laboratory Animals journal. She is passionate about advancing human-relevant, non-animal research methods.

Erica Bremner Kneipp

Independent Chair of Non-Animal Technologies Network (NAT-Net)


Erica has led the establishment of the MRFF, BTF and national clinical trial reform with Commonwealth Health. With CSIRO she was a driving force behind the CSIRO Futures report on NAMs. She is the Executive Director, Research for the National Breast Cancer Foundation and a NED with Brandon BioCatalyst, AusBiotech and BioPlatforms Australia.  

Dr Kathrin Herrmann

Centre for Alternatives to Animal Testing, Johns Hopkins University


Dr. Kathrin Herrmann is a veterinary specialist in Animal Welfare Science, Ethics & Law with a PhD in Biomedical Sciences. Since 2017, she has been at the Johns Hopkins Center for Alternatives to Animal Testing (CAAT), where she leads education and training and works internationally to advance animal-free, human-relevant research and innovation.

Prof Wojciech Chrzanowski

The Medical Advances Without Animals Trust (MAWA)


Professor Wojciech Chrzanowski is an international leader in nanomedicine, extracellular vesicles, nanosafety and biomanufacturing. At the University of Sydney, he leads research developing next-generation therapeutics for tissue regeneration, rare diseases and healthy ageing. His work integrates advanced nano-characterisation, disease models and innovative biomedical technologies to accelerate safer, personalised treatments across human and animal health.

Panelists

Panel 1 – Building Confidence and Capability in NAMs

Dr Michelle Lam

Director, Clinical Translation and Commercialisation MedTech Program, AUScelerate
With extensive experience in research translation and management across academic and clinical settings, Michelle has supported research programs at Monash University, WEHI and the University of Melbourne. She brings expertise in biomedical research, operational management and commercialisation.

Michael Phelan

Principal Consultant, InnovApproach Consulting
With expertise in biotech, pharma and medtech innovation, Michael specialises in guiding the regulatory qualification and adoption of NAMs. He led the first submission accepted into FDA’s ISTAND qualification program and combines technical expertise with strategic leadership to accelerate the translation of innovative science into regulatory practice.

Leanne Weekes

Director of Research and Policy, Bellberry Limited
Leanne is Director of Research and Policy at Bellberry Limited, where she leads initiatives to strengthen clinical research, ethics review, participant welfare and sector collaboration. She previously led CT:IQ and has 12 years’ experience in biopharmaceutical research and development, including managing clinical trials across Australia, New Zealand, the UK and Northern Europe.

Dr Christos Papadimitriou

Chief Executive Officer and Managing Director, Tessara Therapeutics
Christos is a neuroscientist and Founder and CEO of Tessara Therapeutics. He leads the development of RealBrain®, a human neural micro-tissue platform for neurological drug discovery. His work advances human-relevant disease models to improve translational outcomes, accelerate therapeutic development and reduce reliance on animal models in biomedical research.

Panel 2 – Data sharing, services, resources and national infrastructure

Professor Michael Dobbie

CEO, Phenomics Australia (NCRIS provider)
Professor Michael Dobbie is CEO of Phenomics Australia, leading Australia’s preclinical modelling ecosystem. He oversees the development of animal, cellular and computational models to accelerate disease discovery and therapeutic development, including national capability in NAMs. Michael has over 20 years’ research experience across genetics, cancer, neuroscience, metabolism and developmental biology.

Professor Jennifer Byrne

Director of Biobanking, NSW Health; Conjoint Professor of Molecular Oncology, USYD
Professor Jennifer Byrne is Director of Biobanking at NSW Health, leading the NSW Health biobanking programme and Statewide Biobank. With extensive experience establishing and overseeing cancer biobanks, she has led statewide and national biobanking initiatives and contributes to advancing research infrastructure through roles with national and advisory groups.

Dr Nathan Gödde

Manager, The Australian Organoid Facility, University of Queensland
Nathan develops stem cell-derived organoid models to support research and industry applications. His work combines automation, imaging and advanced analysis to improve reproducibility and scalability, advancing organoids as reliable tools for discovery science and reducing reliance on animal models.

Dr MJ Chua

Director of Programs, Therapeutic Innovation Australia
MJ is Director of Programs at Therapeutic Innovation Australia, where she leads initiatives supporting translational research and therapeutic development infrastructure. With a PhD and background in medicinal and drug discovery research, she contributes to advancing national capabilities in biologics, vaccines, cell and gene therapies, RNA products and small molecule therapeutics.

Sign-on Commitments

The future of science is animal-free — be part of the change and join the steering group!

National Collaborative Platform for NAMs – Steering Group

Join other leading stakeholders from across the Australian science ecosystem to establish a National Collaborative Platform for Non-Animal Technologies, building on CSIRO’s 2023 Non-Animal Models Strategy for Australia.

Optional
Name
(Your email will not be publicly displayed)

Stay informed

Sign up to receive all the latest news and updates with our e-newsletter.

Want to be notified via SMS? Click here to opt-in for SMS alerts.